We’ve created additional resources to address your questions:
Esperoct®
[antihemophilic factor (recombinant), glycopegylated-exei]
For US Health Care Professionals Only
![Esperoct® [antihemophilic factor (recombinant), glycopegylated-exei]](/content/dam/novonordisk/esperoctpro/global/esperoct-logo.png){kind=logo}
For US Health Care Professionals Only
Qualifying patients can apply for the Product Assistance Program by downloading and completing the form, or calling 1-844-668-6732 for more information.a
aThe Novo Nordisk Patient Assistance Program (PAP) is administered by NovoSecure™. To qualify for the PAP, patients must demonstrate financial need and must have attempted to find alternative reimbursement. Several factors are considered in evaluating financial need, including cost of living, size of household, and burden of total medical expenses. If the applicant qualifies under the PAP guidelines, a limited supply of the requested medication(s) will be shipped to the patient. Patients who qualify for PAP may be eligible to receive the prescribed Novo Nordisk product, for up to 1 year from the approval date. Product limits vary.
Esperoct® [antihemophilic factor (recombinant), glycopegylated-exei] is indicated for use in adults and children with hemophilia A for on-demand treatment and control of bleeding episodes, perioperative management of bleeding, and routine prophylaxis to reduce the frequency of bleeding episodes.
